- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04326881
A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects
A Single-Center, Randomized, Parallel, Open-Label Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects
Study Overview
Detailed Description
This study will be a single-center, randomized, parallel, open-label, single dosing (SHR-1314 240mg) bridging study in healthy subjects to evaluate the pharmacokinetics and safety of two formulations of SHR-1314.
The study will consist of a 14-days screening period (-14~-1 days); an observation period (1-3 days) and the follow-up period (4-113 days); Subjects will be randomly assigned to three group.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Qian Xu, Ph.D.
- Phone Number: 0186 021-68868370
- Email: xuqian@hrglobe.cn
Study Contact Backup
- Name: Jianwen Chen, Ph.D.
- Phone Number: 0186 021-68868370
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent must be obtained before any assessment is performed.Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed. Where relevant, a legal representative will also sign the informed study consent according to local laws and regulations.
- Men or women at least 18 years and no more than 45 years of age at time of screening.
- Men with a body weight ≥50 kg or women with a body weight ≥45kg, with BMI range from 18 to 25.
- Subjects with normal physical examination results and with normal laboratory results (blood, chemistry, urine, drug screening, coagulation function test), ECG and X-ray chest test are normal or with certain abnormal without clinical significance.
Exclusion Criteria:
- Presence of significant medical problems, with investigator's judge that not proper to participate clinical study
- History of hypersensitivity to any of study drug constituent
- History or current infection with human immunodeficiency virus (HIV) or hepatitis C; or current hepatitis B infection or syphilis
- History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years
- History of chronic or recurrent infectious disease, or evidence of active or latent tuberculosis infection.
- Those who have participated in any clinical study for any drug or medical device within 3 months before screening
- Those who have been vaccinated with live attenuated vaccine within 12 weeks prior to screening
- History or evidence of ongoing alcohol or drug abuse, within the last six months before Baseline.
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
- Subjects judged by the investigator as unsuitable for participating in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SHR-1314 A
single dosing SHR-1314 A
|
single dosing
|
Experimental: SHR-1314 B
single dosing SHR-1314 B
|
single dosing
|
Experimental: SHR-1314 C
single dosing SHR-1314 C
|
single dosing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC0-last: Area under the serum concentration-time curve from time zero to the last measurable concentration
Time Frame: from Day1 to Day113
|
Compare the AUC0-last of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects
|
from Day1 to Day113
|
Cmax: Observed maximum serum concentration
Time Frame: from Day1 to Day113
|
Compare the Cmax of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects
|
from Day1 to Day113
|
AUC0-∞: Area under the serum concentration-time curve from time zero to infinity
Time Frame: from Day1 to Day113
|
Compare the AUC0-∞ of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects
|
from Day1 to Day113
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax : Time at which observed maximum concentration occurs
Time Frame: from Day1 to Day113
|
Compare the Tmax of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects
|
from Day1 to Day113
|
CL/F: Apparent clearance
Time Frame: from Day1 to Day113
|
Compare the CL/F of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects
|
from Day1 to Day113
|
t1/2: Terminal half-life
Time Frame: from Day1 to Day113
|
Compare the t1/2 of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects
|
from Day1 to Day113
|
Incidence and severity of adverse events (AEs).
Time Frame: from Day1 to Day113
|
Compare Incidence and severity of AE at 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects
|
from Day1 to Day113
|
Anti-drug Antibodies (ADAs)
Time Frame: from Day1 to Day113
|
Incidence of development of Anti-drug Antibodies (ADAs) during the course of the study.
|
from Day1 to Day113
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SHR-1314-104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacokinetic
-
University Children's Hospital, ZurichTerminatedPharmacokineticSwitzerland
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Completed
-
Gesynta Pharma ABCTC Clinical Trial Consultants AB; RISE Research Institutes of Sweden ABCompleted
-
Beijing Continent Pharmaceutical Co, Ltd.Completed
-
AstraZenecaCompleted
-
University of OxfordMahidol Oxford Tropical Medicine Research Unit; Faculty of Tropical Medicine...Not yet recruitingHealthy | PharmacokineticThailand
-
AnHeart Therapeutics Inc.Completed
Clinical Trials on SHR-1314
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruitingActive Moderate to Severe Graves' Orbitopathy
-
Jiangsu HengRui Medicine Co., Ltd.CompletedModerate-to-severe Chronic Plaque PsoriasisUnited States, Australia, China
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.RecruitingModerate-to-Severe Plaque PsoriasisChina
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.RecruitingAnkylosing SpondylitisChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Recruiting
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingModerate-to-Severe Plaque Psoriasis
-
Jiangsu HengRui Medicine Co., Ltd.UnknownModerate-to-severe Plaque PsoriasisChina